iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024
iCAD announces major developments at RSNA 2024, including its FDA-cleared ProFound Detection Version 4.0 and a partnership with Cascaid Health.
The collaboration will launch ProFound Health in Q1 2025, offering AI-powered second-read mammography services to expand access to breast health technology. The new Version 4.0 improves aggressive cancer detection by 22% and reduces no-mark cases by 18%.
Clinical data shows significant improvements, including a 23% increase in cancer detection rates and 32% enhanced detection in dense breast tissue.
The company will showcase these innovations at RSNA 2024 in Chicago, December 1-5, featuring presentations on real-world AI implementation results and technical advances.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more